{"id":"W2948405934","doi":"10.1200/jco.19.00882","title":"Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":248,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University; Jewish General Hospital","funders":"National Cancer Institute; American Society of Clinical Oncology","keywords":"Pertuzumab; Medicine; Trastuzumab emtansine; Internal medicine; Hazard ratio; Trastuzumab; Oncology; Breast cancer; Docetaxel; Adverse effect; Cancer; Surgery; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002409769,0.0005789014,0.001184018,0.0001947231,0.0002599707,0.0007228457,0.0004330045,0.0006046284,0.0008020871],"category_scores_gemma":[0.001214951,0.0002228182,0.00147628,0.0002849874,0.0004054499,0.0005106172,0.0003654435,0.001105325,0.0001694849],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006713197,"about_ca_system_score_gemma":0.0007868558,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001138066,"about_ca_topic_score_gemma":0.003528629,"domain_scores_codex":[0.9992076,0.0004635355,0.00005000276,0.00007817226,0.000116838,0.00008385299],"domain_scores_gemma":[0.9988816,0.0002182072,0.0003988604,0.0001180459,0.00006957082,0.000313657],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7894419,0.01518983,0.07154462,0.001000544,0.006278976,0.0002471014,0.0002775949,0.004472166,0.01048358,0.000244575,0.004728026,0.09609105],"study_design_scores_gemma":[0.3393111,0.3024053,0.3297013,0.000248404,0.009017034,0.0008636037,0.0002927934,0.003599746,0.005408572,0.0004361456,0.008601124,0.0001149685],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9940552,0.003564417,0.0002081806,0.0001867071,0.00004056974,0.0002891404,0.0007729915,0.0000139825,0.0008688068],"genre_scores_gemma":[0.9931398,0.002234387,0.0003849454,0.0003990112,0.00009314045,0.0003541187,0.002533225,0.000009348596,0.000852122],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002409769,"threshold_uncertainty_score":0.01274425,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1404453096150034,"score_gpt":0.5111550693327782,"score_spread":0.3707097597177748,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}